Related Experiment Video
Updated: Jul 7, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
Published on: August 14, 2017
Von Willebrand disease: A century of progress
Caterina Casari1, Brooke Sadler2, Sophie Susen3
1Hémostase Inflammation Thrombose (HITh) U1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Abstract:
One hundred years after the initial description of von Willebrand disease, originally referred to as pseudohemophilia, this article is a tribute to Dr Erik von Willebrand and a testament to the progress in our understanding of von Willebrand factor. Main focuses have been on structure and hemostatic function, as well as the advancements in the diagnosis, genetics, and management of von Willebrand disease. Insightful early observations led to the discovery of the main VWF ligands and interaction domains and the molecular mechanisms controlling these associations in the context of hemostasis. Reflecting these intricate mechanisms, the genetics and diagnosis of von Willebrand disease remain challenging, especially for the mild, quantitative deficiencies. Treatment developments and innovations have historically progressed quite slowly and in the shadow of hemophilia. However, recent patient-centered studies underscoring unmet clinical needs have catalyzed a dynamic and rapidly evolving effort to improve patient care and clinical outcomes.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Peripheral Artery Disease I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Rheumatic Heart Disease I: Introduction
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coagulation

